cinepazide

Cinepazide is a small molecule vasodilator primarily used in China for the treatment of cardiovascular and cerebrovascular diseases, as well as peripheral vascular disorders. It acts mainly by potentiating adenosine receptor A2, leading to vasodilation. Additionally, it functions as a weak calcium channel blocker, inhibiting calcium influx into vascular smooth muscle cells and relaxing cerebral vessels, coronary arteries, and peripheral vessels. This results in relief of vasospasm, reduced vascular resistance, improved microcirculation and brain metabolism. Cinepazide also inhibits cAMP phosphodiesterase (increasing cAMP), retards adenosine degradation (enhancing endogenous adenosine effects), inhibits platelet aggregation, reduces blood viscosity, and improves blood rheology. Originally approved in tablet form in 1974 (later withdrawn due to agranulocytosis risk), an injectable formulation was approved in China in 2002 where it remains widely used for acute ischemic stroke and other cerebrovascular conditions[1][5][7].

Brand names

KelinaoAnjieli

Other names

cinepazide maleateCinepazidumCinepazidacinepazide free base